Ironwood Pharmaceuticals Stock Alpha and Beta Analysis
| IRWD Stock | USD 1.49 0.02 1.32% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ironwood Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ironwood Pharmaceuticals over a specified time horizon. Remember, high Ironwood Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ironwood Pharmaceuticals' market risk premium analysis include:
Beta 1.49 | Alpha (0.84) | Risk 6.74 | Sharpe Ratio (0.16) | Expected Return (1.10) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Ironwood |
Ironwood Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ironwood Pharmaceuticals market risk premium is the additional return an investor will receive from holding Ironwood Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ironwood Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ironwood Pharmaceuticals' performance over market.| α | -0.84 | β | 1.49 |
Ironwood Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ironwood Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Ironwood Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ironwood Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Ironwood Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ironwood Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ironwood Pharmaceuticals stock market price indicators, traders can identify Ironwood Pharmaceuticals position entry and exit signals to maximize returns.
Ironwood Pharmaceuticals Return and Market Media
The median price of Ironwood Pharmaceuticals for the period between Mon, Dec 16, 2024 and Sun, Mar 16, 2025 is 3.46 with a coefficient of variation of 39.09. The daily time series for the period is distributed with a sample standard deviation of 1.15, arithmetic mean of 2.95, and mean deviation of 1.09. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Denner Alexander J of 4249 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 12/16/2024 |
2 | Acquisition by Moukheibir Catherine of 22350 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 01/15/2025 |
3 | Acquisition by Currie Mark G of 24311 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 01/17/2025 |
4 | Calculating The Fair Value Of Ironwood Pharmaceuticals, Inc. | 01/23/2025 |
5 | Insider Trading | 01/27/2025 |
6 | Leerink Partnrs Analysts Cut Earnings Estimates for IRWD | 02/05/2025 |
7 | Disposition of 12052 shares by Greg Martini of Ironwood Pharmaceuticals at 1.76 subject to Rule 16b-3 | 02/10/2025 |
8 | Ironwood Pharmaceuticals CFO sells shares worth 21,211 - MSN | 02/13/2025 |
9 | Ironwood Pharmaceuticals Projected to Post Earnings on Thursday | 02/19/2025 |
10 | Ironwood Pharmaceuticals Inc Q4 2024 Earnings Report Preview What To Look For | 02/26/2025 |
11 | Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results Achieves 2024 Financial Guidance | 02/27/2025 |
12 | Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call Transcript | 02/28/2025 |
13 | Acquisition by Shetzline Michael of 34936 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 03/05/2025 |
About Ironwood Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ironwood or other stocks. Alpha measures the amount that position in Ironwood Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | Payables Turnover | 2.94 | 12.04 | 12.65 | Days Of Inventory On Hand | 321.76 | 370.02 | 560.14 |
Ironwood Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Ironwood Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ironwood Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ironwood Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ironwood Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Ironwood Pharmaceuticals' management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ironwood Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Ironwood Pharmaceuticals Backtesting, Ironwood Pharmaceuticals Valuation, Ironwood Pharmaceuticals Correlation, Ironwood Pharmaceuticals Hype Analysis, Ironwood Pharmaceuticals Volatility, Ironwood Pharmaceuticals History and analyze Ironwood Pharmaceuticals Performance. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Ironwood Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.